536565
NOVELIX
Start SIP
Invest Now
Start SIP in NOVELIX
Performance
- Low
- ₹63
- High
- ₹67
- 52 Week Low
- ₹25
- 52 Week High
- ₹70
- Open Price₹66
- Previous Close₹64
- Volume4,547
- 50 DMA₹59.24
- 100 DMA₹55.06
- 200 DMA₹46.46
Investment Returns
- Over 1 Month + 15.47%
- Over 3 Month -6.17%
- Over 6 Month + 51.85%
- Over 1 Year + 147.34%
Smart Investing Starts Here Start SIP with Novelix Pharmaceuticals for Steady Growth!
Novelix Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 60.5
- PEG Ratio
- 0.1
- Market Cap Cr
- 110
- P/B Ratio
- 3.8
- Average True Range
- 3.92
- EPS
- -
- Dividend Yield
- 0
- MACD Signal
- 1.21
- RSI
- 56.37
- MFI
- 59.11
Novelix Pharmaceuticals Financials
Novelix Pharmaceuticals Technicals
EMA & SMA
Current Price
₹62.70
-1.51
(-2.35%)
- Bearish Moving Average 3
- Bullish Moving Average 13
- 20 Day
- ₹61.37
- 50 Day
- ₹59.24
- 100 Day
- ₹55.06
- 200 Day
- ₹46.46
Resistance and Support
64.15
- R3 70.31
- R2 68.65
- R1 65.81
- S1 61.31
- S2 59.65
- S3 56.81
Novelix Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends
| Date | Purpose | Remarks |
|---|---|---|
| 2026-02-12 | Quarterly Results | |
| 2025-11-13 | Quarterly Results | |
| 2025-08-14 | Quarterly Results & A.G.M. | |
| 2025-06-24 | Others | Inter alia, to consider and approve 1. The conversion of Warrants into Equity Shares of the Company. |
| 2025-05-27 | Audited Results |
Novelix Pharmaceuticals F&O
About Novelix Pharmaceuticals
- NSE Symbol
- NOVELIX
- BSE Symbol
- 536565
- ISIN
- INE314I01036
Similar Stocks to Novelix Pharmaceuticals
Novelix Pharmaceuticals FAQs
Novelix Pharmaceuticals share price is ₹62 As on 20 February, 2026 | 03:07
The Market Cap of Novelix Pharmaceuticals is ₹110.4 Cr As on 20 February, 2026 | 03:07
The P/E ratio of Novelix Pharmaceuticals is 60.5 As on 20 February, 2026 | 03:07
The PB ratio of Novelix Pharmaceuticals is 3.8 As on 20 February, 2026 | 03:07
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.